Other · developed by Lantheus Medcl
Perflutren is an ultrasound contrast agent made of liposome-encapsulated microspheres containing the fluorocarbon gas perflutren, which are activated before use. The microspheres have lower acoustic impedance than blood and enhance its backscatter, opacifying the left ventricular chamber and delineating the endocardial border during echocardiography.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Mar 13, 2024). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01490892 | Phase 4 | Breast Cancer | Completed | LNTH |
| NCT00918866 | Phase 4 | Pulmonary Heart Disease | Completed | LNTH |
| NCT00625365 | Phase 4 | Cardiovascular Disease | Completed | LNTH |
| NCT00162370 | Phase 4 | Coronary Artery Disease | Completed | LNTH |
| NCT02764801 | Phase 3 | Hepatocellular Carcinoma | Completed | LNTH |
| NCT03907657 | Phase 2 | Von-Hippel Lindau | Completed | LNTH |
| NCT03297112 | Early Phase 1 | Adnexal Mass | Completed | LNTH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Adnexal MassBreast CancerCardiovascular DiseaseChemoembolization, TherapeuticCoronary Artery DiseaseHeart DiseaseHepatocellular CarcinomaKidney Disease, ChronicPulmonary Heart DiseaseVon-Hippel Lindau
Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.
See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LNTH catalysts and pipeline →